L3VLUP
ProSign in

BSX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BSXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BSX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBSXJNJ
Q3 202031 holders, $15.0bn30 holders, $26.2bn
Q4 202035 holders, $13.6bn32 holders, $26.6bn
Q1 202129 holders, $15.7bn31 holders, $25.3bn
Q2 202127 holders, $18.2bn37 holders, $25.6bn
Q3 202127 holders, $18.2bn40 holders, $24.1bn
Q4 202126 holders, $17.4bn33 holders, $25.2bn
Q1 202232 holders, $17.4bn35 holders, $28.2bn
Q2 202230 holders, $14.0bn33 holders, $26.9bn
Q3 202229 holders, $14.5bn36 holders, $25.4bn
Q4 202226 holders, $16.6bn35 holders, $27.6bn
Q1 202332 holders, $18.5bn42 holders, $24.5bn
Q2 202337 holders, $19.6bn38 holders, $25.0bn
Q3 202333 holders, $19.7bn37 holders, $18.9bn
Q4 202330 holders, $20.6bn31 holders, $19.0bn
Q1 202433 holders, $24.0bn32 holders, $19.7bn
Q2 202435 holders, $26.8bn35 holders, $20.4bn
Q3 202440 holders, $28.3bn28 holders, $22.3bn
Q4 202440 holders, $29.4bn37 holders, $20.4bn
Q1 202544 holders, $33.1bn32 holders, $20.5bn
Q2 202544 holders, $33.6bn31 holders, $18.4bn
Q3 202548 holders, $29.5bn32 holders, $23.7bn
Q4 202549 holders, $28.5bn29 holders, $27.8bn
Q1 202645 holders, $17.2bn34 holders, $35.6bn
Q2 202640 holders, $13.0bn33 holders, $39.1bn
BSX

Boston Scientific Corp

Holders
49
Reported value
$28.5bn
Buyers
28
Sellers
22

Breadth +6 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 52 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BSX (23)

Artisan Partners LP, Balyasny Asset Management LLC, Caxton Associates LLP, Citadel Advisors LLC, Egerton Capital UK LLP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Holocene Advisors LP, Jane Street Group LLC, Lone Pine Capital LLC, Maverick Capital Ltd, PDT Partners LLC, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Investments LP, Viking Global Investors LP, Voloridge Investment Management LLC, Walleye Capital LLC, Winton Group Ltd

Only JNJ (3)

Element Capital Management LLC, Markel Group Inc, Rokos Capital Management LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →